Full-Time

Principal Medical Writer

Development

Updated on 3/14/2025

Revolution Medicines

Revolution Medicines

501-1,000 employees

Develops targeted therapies for RAS-driven cancers

Compensation Overview

$204k - $255kAnnually

Senior, Expert

San Carlos, CA, USA

This position is hybrid, requiring some in-office presence at the headquarters in Redwood City, CA.

Category
Technical Writing
Content & Writing
Medical, Clinical & Veterinary
Required Skills
Word/Pages/Docs
Risk Management
Requirements
  • 8+ years of clinical regulatory writing experience within one or more biopharmaceutical companies, including prior experience working as a medical writer on BLA/NDA/MAA
  • Advanced degree in clinical or life sciences, English, journalism and/or communications
  • Proficiency in Microsoft Word, including the use of MS Word styles and templates
  • Familiarity with AMA style
  • Ability to successfully manage and prioritize writing projects with competing deadlines, to foster collaborative cross-functional relationships and to drive high-quality regulatory writing projects to successful submission
  • Ability to work in a high-pressure environment with short deadlines while remaining calm, focused, professional, diplomatic and positive
Responsibilities
  • Serves as medical writing lead on complex clinical regulatory documents, including protocols, IBs, CSRs, briefing documents, periodic safety reports, risk management documents, and IND and NDA modules
  • Assists in developing and maintaining document templates, department standard processes and work instructions, medical writer onboarding materials, and style guide
  • Serves as primary medical writing contact for one or more clinical development programs
  • Represents medical writing at cross-functional planning meetings
  • Effectively communicates deliverables needed, the writing process, and timelines to team members
  • Schedules document reviews and manages adjudication meetings
  • Independently resolves document content issues and questions
  • Ensures consistency, clarity, and accuracy both within and across documents
  • Recognizes potential scheduling and resource conflicts across projects and provides recommendations to resolve
  • Mentors junior and contract medical writers on both document and timeline management
Desired Qualifications
  • Experience with oncology therapeutics
  • Familiarity with PleaseReview, StartingPoint, EndNote, and Smartsheet
  • Experience performing QC reviews of clinical regulatory documents

Revolution Medicines develops treatments specifically for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main product line includes RASON Inhibitors, designed to target and inhibit RAS proteins that contribute to cancer growth. The company uses a Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses solely on RAS-driven cancers, allowing them to tailor their research and development efforts to this specific area. Their goal is to improve cancer treatment outcomes for patients with RAS mutations by providing effective targeted therapies.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Redwood City, California

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of EQRx adds over $1 billion in capital for R&D.
  • FDA fast-tracking supports their RAS-targeted therapy pipeline.
  • Growing interest in targeted cancer therapies boosts investment opportunities.

What critics are saying

  • EQRx acquisition may pose integration challenges and cultural clashes.
  • $600M public stock offering could lead to shareholder dilution.
  • Focus on RAS-addicted cancers limits market scope and increases competition risk.

What makes Revolution Medicines unique

  • Revolution Medicines reconfigures natural substances into best-in-class cancer therapies.
  • Their Tri Complex Inhibitor platform targets RAS proteins driving cancer growth.
  • Exclusive license with University of Illinois enhances their unique synthesis technology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

2%

2 year growth

11%
Stock Titan
Dec 3rd, 2024
Revolution Medicines Launches $600M Public Stock Offering, Plans $90M Option | RVMD Stock News

Clinical-stage oncology company Revolution Medicines announces major public offering of common stock worth $600M, with additional $90M option for underwriters.

RevMed
Feb 21st, 2024
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares | Revolution Medicines

Underwriters’ Full Exercise of Option Brings Gross Proceeds to $179.4 Million REDWOOD CITY, Calif., July 13, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq:RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit elusive frontier targets within

Seeking Alpha
Feb 14th, 2024
Corvex Management buys Illumina, exits Apple, TKO

Corvex Management buys Illumina, exits Apple, TKO.

GlobeNewswire
Nov 1st, 2023
Leading Independent Proxy Advisory Firms Iss And Glass Lewis Recommend Revolution Medicines Stockholders Vote “For” Proposed Acquisition Of Eqrx, Inc.

REDWOOD CITY, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that leading independent proxy advisory firms, Institutional Shareholder Services Inc. ("ISS") and Glass Lewis & Co. ("Glass Lewis"), have recommended Revolution Medicines stockholders vote “FOR” the issuance of Revolution Medicines shares in the previously announced all-stock acquisition of EQRx, Inc. at the special meeting of stockholders scheduled for November 8, 2023.In their respective reports, ISS and Glass Lewis view the proposed transaction as favorable to Revolution Medicines stockholders

PharmaSources
Aug 15th, 2023
EQRx, known as the "TEMU" of the Pharmaceutical Industry, has been Acquired by Revolution Medicines

On August 1st, EQRx announced an agreement with Revolution Medicines to be acquired in an all-stock transaction, which is expected to be completed in November 2023.